[{"id":"626de316-d799-4804-9309-0166aa718911","acronym":"NCI-2018-01296","url":"https://clinicaltrials.gov/study/NCT02983578","created_at":"2021-01-18T14:40:40.387Z","updated_at":"2025-02-25T15:07:25.564Z","phase":"Phase 2","brief_title":"Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer","source_id_and_acronym":"NCT02983578 - NCI-2018-01296","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • STAT3","pipe":" | ","alterations":" PD-L1 expression • STAT3 expression","tags":["CD8 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • STAT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/02/2017","start_date":" 03/02/2017","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-08-27"},{"id":"da2a1d36-30db-440a-9df5-123b9dec43a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06502249","created_at":"2025-02-27T07:46:28.341Z","updated_at":"2025-02-27T07:46:28.341Z","phase":"","brief_title":"Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)","source_id_and_acronym":"NCT06502249","lead_sponsor":"Ain Shams University","biomarkers":" MYC • IL6 • STAT3 • HSP90AA1","pipe":"","alterations":" ","tags":["MYC • IL6 • STAT3 • HSP90AA1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2026","start_date":" 06/01/2026","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-07-16"},{"id":"3cc68517-997b-45c0-9418-e55247f24f07","acronym":"","url":"https://clinicaltrials.gov/study/NCT04414540","created_at":"2024-02-28T17:31:07.888Z","updated_at":"2024-07-02T16:35:17.528Z","phase":"Phase 2","brief_title":"Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients","source_id_and_acronym":"NCT04414540","lead_sponsor":"Trisha Wise-Draper","biomarkers":" IL6 • TNFA • CXCL8 • STAT3 • IL2 • IL10 • IL4 • NKG2D","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • STAT3 • IL2 • IL10 • IL4 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-28"},{"id":"46aa98a6-cba9-44da-9bfb-8a499b69e25d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02671890","created_at":"2024-02-12T16:24:54.341Z","updated_at":"2024-07-02T16:35:19.826Z","phase":"Phase 1","brief_title":"Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02671890","lead_sponsor":"Mayo Clinic","biomarkers":" STAT3 • EGR1 • SOCS3","pipe":"","alterations":" ","tags":["STAT3 • EGR1 • SOCS3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/05/2025","study_completion_date":" 05/05/2025","last_update_posted":"2024-02-12"},{"id":"eb372b62-ee59-4346-9e79-7fe21ffd6215","acronym":"NCI-2022-02385","url":"https://clinicaltrials.gov/study/NCT05592015","created_at":"2022-10-24T13:57:03.902Z","updated_at":"2024-07-02T16:35:21.586Z","phase":"Phase 2","brief_title":"Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia","source_id_and_acronym":"NCT05592015 - NCI-2022-02385","lead_sponsor":"John Reneau","biomarkers":" CD8 • STAT3 • B3GAT1","pipe":" | ","alterations":" STAT3 mutation","tags":["CD8 • STAT3 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-31"},{"id":"e86d670d-ff10-4e93-b7c9-1b7a0035cc36","acronym":"","url":"https://clinicaltrials.gov/study/NCT06230965","created_at":"2024-01-30T20:21:16.537Z","updated_at":"2024-07-02T16:35:21.824Z","phase":"","brief_title":"Clinical Study of Lung Protective Ventilation Strategies and Tumor Microenvironment","source_id_and_acronym":"NCT06230965","lead_sponsor":"Affiliated Hospital of Nantong University","biomarkers":" VEGFA • IL6 • TNFA • JAK1 • STAT3 • MMP2 • MMP9","pipe":"","alterations":" ","tags":["VEGFA • IL6 • TNFA • JAK1 • STAT3 • MMP2 • MMP9"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 60","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-30"},{"id":"0873a687-5c25-4715-8acf-d74951c994f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654547","created_at":"2023-11-24T18:58:25.547Z","updated_at":"2024-07-02T16:35:24.753Z","phase":"Phase 1","brief_title":"Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer","source_id_and_acronym":"NCT03654547","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-01-03"},{"id":"46872237-6ce2-4f9c-9626-78292d387d52","acronym":"CanStem111P trial","url":"https://clinicaltrials.gov/study/NCT02993731","created_at":"2023-11-15T19:14:20.299Z","updated_at":"2024-07-02T16:35:29.170Z","phase":"Phase 3","brief_title":"A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT02993731 - CanStem111P trial","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 1134","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2023-11-15"},{"id":"2616fda1-27bb-45e0-aa28-222708cf4e67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05014360","created_at":"2021-08-20T14:52:57.168Z","updated_at":"2024-07-02T16:35:46.607Z","phase":"Phase 1b","brief_title":"A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis","source_id_and_acronym":"NCT05014360","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" APC • STAT3","pipe":" | ","alterations":" APC mutation","tags":["APC • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 11/10/2021","start_date":" 11/10/2021","primary_txt":" Primary completion: 02/15/2023","primary_completion_date":" 02/15/2023","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2023-06-02"},{"id":"482e7013-1999-408a-b155-ce153c0cce4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05363826","created_at":"2022-05-06T18:55:04.191Z","updated_at":"2024-07-02T16:35:50.709Z","phase":"Phase 1","brief_title":"Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®","source_id_and_acronym":"NCT05363826","lead_sponsor":"Photolitec LLC","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/11/2023","start_date":" 04/11/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-04-13"},{"id":"4992c086-2aab-4254-878a-7ce1b1e555fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04334863","created_at":"2021-01-18T20:59:17.912Z","updated_at":"2024-07-02T16:35:55.122Z","phase":"Phase 1","brief_title":"WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors","source_id_and_acronym":"NCT04334863","lead_sponsor":"Emory University","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WP1066"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/04/2020","start_date":" 05/04/2020","primary_txt":" Primary completion: 02/03/2023","primary_completion_date":" 02/03/2023","study_txt":" Completion: 02/03/2023","study_completion_date":" 02/03/2023","last_update_posted":"2023-02-21"},{"id":"b2290004-6a3b-4c7e-a7e3-aba3da3fec16","acronym":"","url":"https://clinicaltrials.gov/study/NCT01423851","created_at":"2022-03-09T16:52:40.614Z","updated_at":"2024-07-02T16:36:15.706Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF","source_id_and_acronym":"NCT01423851","lead_sponsor":"NS Pharma, Inc.","biomarkers":" JAK2 • CD8 • IL6 • STAT3 • CD14","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CD8 • IL6 • STAT3 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 04/22/2020","primary_completion_date":" 04/22/2020","study_txt":" Completion: 04/22/2020","study_completion_date":" 04/22/2020","last_update_posted":"2022-03-09"},{"id":"49dcbbff-6ced-48b8-82ea-1df1dba75ce8","acronym":"BAZE","url":"https://clinicaltrials.gov/study/NCT04812808","created_at":"2021-03-24T16:10:47.311Z","updated_at":"2024-07-02T16:36:16.409Z","phase":"","brief_title":"Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT04812808 - BAZE","lead_sponsor":"Hôpital Fribourgeois","biomarkers":" IL6 • STAT3","pipe":" | ","alterations":" STAT3 expression • IL6 expression","tags":["IL6 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 expression • IL6 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2022-02-25"},{"id":"8ab9b326-945d-42b1-83a2-bd1ce3110fd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03180528","created_at":"2021-01-18T15:41:05.915Z","updated_at":"2024-07-02T16:36:29.416Z","phase":"Phase 2","brief_title":"Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer","source_id_and_acronym":"NCT03180528","lead_sponsor":"Kavita Sarin","biomarkers":" STAT3 • GLI1","pipe":"","alterations":" ","tags":["STAT3 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e remetinostat (SHP-141)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2018","start_date":" 07/07/2018","primary_txt":" Primary completion: 07/07/2020","primary_completion_date":" 07/07/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2021-06-08"},{"id":"a1b1fa8f-46bb-4fd0-92bc-ce0c17e75e92","acronym":"","url":"https://clinicaltrials.gov/study/NCT01702064","created_at":"2021-01-18T07:24:12.665Z","updated_at":"2024-07-02T16:36:36.570Z","phase":"Phase 1","brief_title":"Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients","source_id_and_acronym":"NCT01702064","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • nilotinib"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 02/21/2013","start_date":" 02/21/2013","primary_txt":" Primary completion: 10/17/2016","primary_completion_date":" 10/17/2016","study_txt":" Completion: 01/09/2019","study_completion_date":" 01/09/2019","last_update_posted":"2021-01-05"},{"id":"65879970-940d-49a4-bf2d-eb502d2401a1","acronym":"AflacST1402","url":"https://clinicaltrials.gov/study/NCT02390843","created_at":"2021-01-18T11:23:57.025Z","updated_at":"2024-07-02T16:36:46.711Z","phase":"Phase 1","brief_title":"Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors","source_id_and_acronym":"NCT02390843 - AflacST1402","lead_sponsor":"Emory University","biomarkers":" STAT3 • IL6R","pipe":"","alterations":" ","tags":["STAT3 • IL6R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • topotecan • simvastatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 09/22/2019","primary_completion_date":" 09/22/2019","study_txt":" Completion: 09/22/2019","study_completion_date":" 09/22/2019","last_update_posted":"2020-04-03"},{"id":"0aa17be4-1019-48c2-aae6-8e7c68526412","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522649","created_at":"2022-06-12T05:56:57.860Z","updated_at":"2024-07-02T16:36:58.810Z","phase":"Phase 3","brief_title":"A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03522649","lead_sponsor":"1Globe Health Institute LLC","biomarkers":" CTNNB1 • STAT3","pipe":"","alterations":" ","tags":["CTNNB1 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • napabucasin (BBI608)"],"overall_status":"Unknown status","enrollment":" Enrollment 668","initiation":"Initiation: 04/12/2018","start_date":" 04/12/2018","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-06-18"},{"id":"30b96175-0a83-421c-ac2a-98331e1f2ae0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00084318","created_at":"2021-01-18T00:14:27.093Z","updated_at":"2024-07-02T16:37:04.723Z","phase":"Phase 2","brief_title":"Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck","source_id_and_acronym":"NCT00084318","lead_sponsor":"Radiation Therapy Oncology Group","biomarkers":" EGFR • STAT3 • CCNB1","pipe":"","alterations":" ","tags":["EGFR • STAT3 • CCNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 238","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 03/01/2009","primary_completion_date":" 03/01/2009","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2018-12-12"},{"id":"6f30492d-9b05-4091-b637-35cf7b20203d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01140178","created_at":"2021-01-18T04:32:01.280Z","updated_at":"2024-07-02T16:37:06.074Z","phase":"Phase 1","brief_title":"A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx","source_id_and_acronym":"NCT01140178","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 06/08/2010","start_date":" 06/08/2010","primary_txt":" Primary completion: 01/29/2013","primary_completion_date":" 01/29/2013","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2018-10-16"},{"id":"34daa706-9096-4fce-9a76-dd0af1cf295c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01563302","created_at":"2021-01-18T06:37:34.260Z","updated_at":"2025-02-25T15:05:13.817Z","phase":"Phase 1/2","brief_title":"Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers","source_id_and_acronym":"NCT01563302","lead_sponsor":"Ionis Pharmaceuticals, Inc.","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e danvatirsen (AZD9150)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 02/27/2012","start_date":" 02/27/2012","primary_txt":" Primary completion: 03/23/2016","primary_completion_date":" 03/23/2016","study_txt":" Completion: 03/23/2016","study_completion_date":" 03/23/2016","last_update_posted":"2018-06-25"},{"id":"9e3d8f1b-a521-4353-a085-fa222ff26efb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02680951","created_at":"2021-01-18T13:04:24.331Z","updated_at":"2024-07-02T16:37:11.385Z","phase":"Phase 1","brief_title":"Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia","source_id_and_acronym":"NCT02680951","lead_sponsor":"Emory University","biomarkers":" KIT • STAT3","pipe":" | ","alterations":" KIT expression","tags":["KIT • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • idarubicin hydrochloride • fludarabine IV • Depocyte (liposomal cytarabine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 12/15/2017","primary_completion_date":" 12/15/2017","study_txt":" Completion: 12/15/2017","study_completion_date":" 12/15/2017","last_update_posted":"2018-04-19"},{"id":"f3d6b05f-3b8f-4428-a7d4-82d5031c9793","acronym":"","url":"https://clinicaltrials.gov/study/NCT01568996","created_at":"2021-01-18T06:39:24.188Z","updated_at":"2024-07-02T16:37:14.979Z","phase":"Phase 1","brief_title":"Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions","source_id_and_acronym":"NCT01568996","lead_sponsor":"John Kirkwood","biomarkers":" ALK • STAT3","pipe":" | ","alterations":" STAT3 expression","tags":["ALK • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 expression"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2018-01-09"},{"id":"10d15577-1976-4637-a837-428e95cca323","acronym":"","url":"https://clinicaltrials.gov/study/NCT01009437","created_at":"2021-01-18T03:56:59.867Z","updated_at":"2024-07-02T16:37:15.831Z","phase":"Phase 1/2","brief_title":"Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer","source_id_and_acronym":"NCT01009437","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA • STAT3 • HSPA5 • ATF4 • HSP90AA1","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR • IL6 • TNFA • STAT3 • HSPA5 • ATF4 • HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ritonavir"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 05/26/2010","start_date":" 05/26/2010","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2017-12-05"},{"id":"0214d5af-0cfe-4ce0-8f49-2e63e81209fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01749384","created_at":"2021-01-18T07:40:25.968Z","updated_at":"2024-07-02T16:37:17.150Z","phase":"Phase 1","brief_title":"Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01749384","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/06/2012","start_date":" 12/06/2012","primary_txt":" Primary completion: 05/24/2016","primary_completion_date":" 05/24/2016","study_txt":" Completion: 05/24/2016","study_completion_date":" 05/24/2016","last_update_posted":"2017-10-12"}]